Physician profile
Jose E Alonso
NPI 1386095206
$1,714.71
in general payments reported to CMS, 2019-2025
11 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what 79% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $214 · 2023: $320 · 2024: $170 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,500.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dilon Technologies, INC. | $321.01 | 2025 | Hemoblast Bellows |
| Kerecis Limited | $291.57 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Inspire Medical Systems, INC. | $238.82 | 2022-2023 | Inspire |
| Integra Lifesciences Corporation | $195.67 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Medtronic, INC. | $187.37 | 2025 | Propel |
| Smith+Nephew, INC. | $147.50 | 2024 | Pico 14 |
| Axogen | $125.00 | 2025 | |
| Intersect Ent, INC. | $82.14 | 2022 | |
| Optinose US, INC. | $45.81 | 2024-2025 | |
| Glaxosmithkline, LLC. | $42.08 | 2025 | Nucala |
| Hikma Pharmaceuticals USA | $37.74 | 2023-2025 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Alonso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.